

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Lonafarnib

February 10, 2026

Therapeutic category

Agents affecting metabolism, n.e.c. (not elsewhere classified)

Non-proprietary name

Lonafarnib

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision						
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Quinidine sulfate hydrate, bepridil hydrochloride hydrate, ticagrelor, eplerenone, ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, methylergometrine maleate, triazolam, anamorelin hydrochloride, ivabradine hydrochloride, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small cell lymphocytic lymphoma)], ibrutinib, blonanserin, lurasidone hydrochloride, azelnidipine containing preparations, suvorexant, tadalafil (Adcirca), vardenafil hydrochloride hydrate, lomitapide mesilate, rifabutin, finerenone, rivaroxaban, <u>riociguat</u>, apalutamide, carbamazepine, midazolam, atorvastatin calcium hydrate containing preparations, simvastatin</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table border="1" data-bbox="241 1219 1115 1412"> <thead> <tr> <th data-bbox="241 1219 434 1321">Drugs</th> <th data-bbox="434 1219 833 1321">Signs, symptoms, and treatment</th> <th data-bbox="833 1219 1115 1321">Mechanism/risk factors</th> </tr> </thead> <tbody> <tr> <td data-bbox="241 1321 434 1412"><u>Riociguat</u></td> <td data-bbox="434 1321 833 1412"><u>Lonafarnib may increase the blood concentration of</u></td> <td data-bbox="833 1321 1115 1412"><u>It is considered that the clearance of</u></td> </tr> </tbody> </table>	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	<u>Riociguat</u>	<u>Lonafarnib may increase the blood concentration of</u>	<u>It is considered that the clearance of</u>	<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Quinidine sulfate hydrate, bepridil hydrochloride hydrate, ticagrelor, eplerenone, ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, methylergometrine maleate, triazolam, anamorelin hydrochloride, ivabradine hydrochloride, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small cell lymphocytic lymphoma)], ibrutinib, blonanserin, lurasidone hydrochloride, azelnidipine containing preparations, suvorexant, tadalafil (Adcirca), vardenafil hydrochloride hydrate, lomitapide mesilate, rifabutin, finerenone, rivaroxaban, <u>apalutamide</u>, carbamazepine, midazolam, atorvastatin calcium hydrate containing preparations, simvastatin</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <p>(Deleted)</p>
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors					
<u>Riociguat</u>	<u>Lonafarnib may increase the blood concentration of</u>	<u>It is considered that the clearance of</u>					

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

	<u>riociguat.</u>	<u>riociguat is decreased by the inhibitory activity of lonafarnib against CYP3A and P-glycoprotein.</u>									
<p>10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)</p> <p>(N/A)</p>			<p>10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)</p> <table border="1" data-bbox="1137 678 2004 1211"> <thead> <tr> <th data-bbox="1137 678 1337 778">Drugs</th> <th data-bbox="1337 678 1727 778">Signs, symptoms, and treatment</th> <th data-bbox="1727 678 2004 778">Mechanism/risk factors</th> </tr> </thead> <tbody> <tr> <td data-bbox="1137 778 1337 1211"><u>Riociguat</u></td> <td data-bbox="1337 778 1727 1211"><u>Lonafarnib may increase the blood concentration of riociguat. When co-administration with lonafarnib is necessary, patients should be monitored for their condition and dose reduction of riociguat should be considered as necessary.</u></td> <td data-bbox="1727 778 2004 1211"><u>The metabolism of riociguat is suppressed by the inhibitory activity of lonafarnib against CYP3A.</u></td> </tr> </tbody> </table>			Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	<u>Riociguat</u>	<u>Lonafarnib may increase the blood concentration of riociguat. When co-administration with lonafarnib is necessary, patients should be monitored for their condition and dose reduction of riociguat should be considered as necessary.</u>	<u>The metabolism of riociguat is suppressed by the inhibitory activity of lonafarnib against CYP3A.</u>
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors									
<u>Riociguat</u>	<u>Lonafarnib may increase the blood concentration of riociguat. When co-administration with lonafarnib is necessary, patients should be monitored for their condition and dose reduction of riociguat should be considered as necessary.</u>	<u>The metabolism of riociguat is suppressed by the inhibitory activity of lonafarnib against CYP3A.</u>									

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.